Trial Profile
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- Acronyms PATRICIA
- Sponsors Genentech
- 04 May 2021 Primary analysis of efficacy endpoint at data cut-off May 2019, published in the Journal of Clinical Oncology
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 16 Mar 2020 Planned End Date changed from 30 Mar 2020 to 31 Mar 2021.